Wells Fargo’s Amicus Therapeutics FOLD Stock Holding History

Wells Fargo’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-45,000	Closed	-$31K	–	6399
2018 Q1	$31K	Hold	45,000	–	–	﹤0.01%	5708
2017 Q4	$105K	Buy	+45,000	New	+$618K	﹤0.01%	5286
2017 Q1	–	Sell	-24,000	Closed	-$49K	–	6361
2016 Q4	$49K	Hold	24,000	–	–	﹤0.01%	5375
2016 Q3	$31K	Buy	+24,000	New	+$162K	﹤0.01%	5478

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Wells Fargo's FOLD Position: Q1 2026 in Review

Wells Fargo reduced its Amicus Therapeutics (FOLD) stake by 67% in Q1 2026, selling an estimated $3.27M and leaving 111,070 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #3433.

Wells Fargo first reported a position in FOLD in Q2 2013 and has held it in 47 quarters since. The position peaked at $42.5M in Q1 2018. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Wells Fargo held 111,070 shares of Amicus Therapeutics worth $1.61M as of Q1 2026.
Wells Fargo sold 228,356 Amicus Therapeutics shares in Q1 2026, an estimated $3.27M.
Amicus Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3433 holding.
Wells Fargo first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 47 quarters since.
Wells Fargo's Amicus Therapeutics position peaked at $42.5M in Q1 2018.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.